Over the past decade, the increasing incidence of diseases such as cystic fibrosis, chronic pancreatitis, and diabetes has significantly contributed to the growth of the global exocrine pancreatic insufficiency (EPI) market. The incidence of EPI is markedly observed in patients suffering from cystic fibrosis. According to the Cystic Fibrosis Foundation, a non-profit organization in the United States, about 70,000 people worldwide are living with cystic fibrosis (CF), with around 30,000 people living with CF in the U.S. alone. In addition, 1,000 new cases of cystic fibrosis are diagnosed every year in the U.S., which is expected to augment the market growth in the forthcoming years. The global exocrine pancreatic insufficiency market was valued at US$707.0 mn in 2014 and is projected to reach US$1,588.8 mn by 2023, registering a CAGR of 8.3% from 2015 to 2023.
The report provides a comprehensive analysis of drivers, restraints, and opportunities that are impacting the market’s trajectory across various segments. To provide an in-depth analysis, the report broadly segments the exocrine pancreatic insufficiency market based on therapeutics, diagnostic test, and geography.
To provide an accurate and in-depth analysis of the market dynamics, the report provides up-to-date and pertinent data on the size and share of different segments in key geographical regions. The study provides a comparative analysis of the market shares of major players in exocrine pancreatic insufficiency market. In addition, the emerging business strategies and plans analyzed in the report are intended to help market players, established as well as new entrants, to create effective strategies for growth across regions.
This 71 page report gives readers a comprehensive overview of the Exocrine Pancreatic Insufficiency Market. Browse through 11 data tables and 19 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/exocrine-pancreatic-insufficiency.html
The incidence of EPI is expected to rise dramatically due to the increasing incidence of diseases such as cystic fibrosis, chronic pancreatitis, and diabetes. This is in turn propelling the growth of the exocrine pancreatic insufficiency market across the globe. Advancements in pancreatic enzyme replacement therapies are anticipated to offer vast growth opportunities for players in the exocrine pancreatic insufficiency market.
In addition, developments witnessed in the market are fuelled by the demand for more reliable treatments for EPI and increasing availability of medications with enhanced efficacy in different developing countries. For instance, the rising disposable incomes and significant improvements in healthcare infrastructure in emerging economies such as India, China, and Malaysia are expected to offer momentum to the market.
Ultresa, an orally administered porcine pancreatic enzyme preparation (PEP), is anticipated to exhibit a high CAGR since it is more technologically advanced compared to other similar PERT products. As a result, the market is expected to witness tremendous demand for Ultresa. Advancements in diagnostic technologies have led to the adoption of magnetic resonance imaging (MRI) as the preferred radiological imaging modality for the assessment of chronic pancreatitis.
Get accurate market forecast and analysis on the Exocrine Pancreatic Insufficiency Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2748
North America is expected to account for the maximum share in the global exocrine pancreatic insufficiency (EPI) market along the forecast period. The demand will be chiefly driven by the increasing prevalence of exocrine pancreatic insufficiency and other causative diseases such as cystic fibrosis (CF) and chronic pancreatitis (CP) in the U.S. However, Asia Pacific is projected to exhibit the most promising CAGR during the forecast period; the growth will be driven by a rise in geriatric population in countries such as Japan, China, and Singapore. Furthermore, the exocrine pancreatic insufficiency market in Latin America is projected to register a significant CAGR through the forecast period.
To offer a detailed competitive landscape and in-depth strategic assessment of the market players, the report extensively profiles companies such as AbbVie, Inc., Nordmark Arzneimittel GmbH & Co. KG, Allergan plc, Digestive Care, Inc., and Janssen Pharmaceuticals, Inc. The strategic assessment includes the recent product launches and key strategies adopted by major market players to consolidate their market positions.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453